| Literature DB >> 22405899 |
Lourdes Cucurull-Sanchez1, Karen G Spink, Sterghios Athanasios Moschos.
Abstract
The pharmaceutical industry is in the process of re-inventing its pipeline in an attempt to overcome its increasing phase II and III attrition rates. Here, we describe how systems pharmacology can be used as a risk assessment tool to alleviate this problem before bringing in larger investments. We propose that this translational research tool could provide a valuable, complementary addition to other emerging innovative approaches for target identification and validation in discovery and, ultimately, for aiding clinical trial optimization.Mesh:
Substances:
Year: 2012 PMID: 22405899 DOI: 10.1016/j.drudis.2012.01.015
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851